Meeting
2019 ASCO Annual Meeting
Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.
Authors
Brian I. Rini
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Brian I. Rini , Robert J. Motzer , Thomas Powles , David F. McDermott , Bernard Escudier , Frede Donskov , Robert E. Hawkins , Sergio Bracarda , Jens Bedke , Ugo De Giorgi , Camillo Porta , Alain Ravaud , Francis Parnis , Enrique Grande , Wei Zhang , Mahrukh A. Huseni , Susheela Carroll , Roxana Ioana Sufan , Christina Schiff , Michael B. Atkins
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT02420821
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4512)
DOI
10.1200/JCO.2019.37.15_suppl.4512
Abstract #
4512
Poster Bd #
338
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).
First Author: David F. McDermott
Poster
2021 ASCO Annual Meeting
Exploratory biomarker findings from cohort 2 of MODUL: An adaptable, phase 2, signal-seeking trial of fluoropyrimidine + bevacizumab ± atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer.
First Author: Josep Tabernero
Poster
2022 ASCO Annual Meeting
FoRT 05-BEAT: A phase II randomized trial comparing atezolizumab versus atezolizumab + bevacizumab as first-line treatment in patients with PD-L1 high advanced/metastatic NSCLC.
First Author: Rita Migliorino
Poster
2021 ASCO Annual Meeting
Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).
First Author: Jose Luis Perez-Gracia